Publications

Selected Publications (Above 10 Impact Factor)

  1. Surrogate reporter-based enrichment of cells containing RNA-guided Cas9 nuclease- induced mutations. Ramakrishna S, Cho SW, Kim S, Song M, Gopalappa R, Kim JS, Kim H. Nature Communications. (IF: 10.015; SCI) (Cited: 7), 2014 Feb 26; 5: 3378.
  2. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Ramakrishna S, Kwaku Dad AB, Beloor J, Gopalappa R, Lee SK, Kim H. Genome Research. (IF: 14.397; SCI) (Cited: 5), 2014, 24:1020-7.
  3. Regulation of pluripotency and differentiation by deubiquitinating enzymes. Suresh B, Lee J, Kim H*, Ramakrishna S*. Cell Death and Differentiation. (IF: 8.1), 2016, 23: 1257-64. (Co-Corresponding Author).
  4. CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods. Jo YI, Suresh B, Kim H, Ramakrishna S. BBA- Reviews on Cancer (IF: 7.584; SCI), 2015, 1856: 234-43. (Corresponding author).
  5. Somatic Mutations in TSC1 and TSC2 cause focal cortical dysplasia. Lim JS, Gopalappa R, Kim SH, Ramakrishna S, Lee M, Kim W, Kim J, Park SM, Lee J, Oh JH, Kim HD, Park CH, Lee JS, Kim S, Kim DS, Han JM, Kang HC, Kim H, Lee JH. American Journal of Human Genetics (IF:11.20), 2017, 100:454-472.
  6. Deubiquitylating enzymes as cancer stem cell therapeutics. Haq S, Suresh B*, Ramakrishna S*. BBA reviews on Cancers (IF: 9.452), 2018, 1869: 1-10 *(Co-corresponding author).
  7. Paired D10A Cas9 nickases are sometimes more efficient than individual nucleases for gene disruption. Gopalappa R, Suresh B, Ramakrishna S* and Kim HH*. Nucleic Acid Research (IF:10.16), 2018, 46(12):e71. *(Co-corresponding author).
  8. Brain somatic mosaicisms in MTOR disrupt neuronal ciliogenesis leading to focal cortical dyslamination. Park SM, Lim JS, Ramakrishna S, Kim SH, Kim WK, Lee J, Kang HC, Reiter JF, Kim DS, Kim HH, Lee JH. Neuron (IF: 14.02), 2020, 27:3004-3020.
  9. En bloc and segmental deletions of human XIST reveal X chromosome inactivation-involving RNA elements. Lee H, Gopalappa R, Hongjae S, Choi S, Ramakrishna S, Lee J, Kim HH, Nam JW. Nucleic Acid Research (IF: 11.5), 2019, 47:3875-3887
  10. Genome-scale screening of deubiquitinase subfamily identifies USP3 as a stabilizer of Cdc25A regulating cell cycle in cancer. Das S, Chandrasekaran AP, Suresh B, Haq S, Kang JH, Lee SJ, Kim J, Kim J, Lee S, Kim HH*, Kim KS* and Ramakrishna S*. Cell Death and Differentiation (IF: 10.1), 2020, 27:3004-3020. *(Co-Corresponding author).
  11. USP32 conferes cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. Chandrasekaran AP, Kaushal K, Park CH, Kim KS* and Ramakrishna S*. Theranostics (IF: 11.6). 2021, 11:9752-9771.*(Co-Corresponding author). 
  12. Redox regulation of DUBs and its therapeutic implications in cancer. Tyagi A, Haq S and Ramakrishna S. Redox Biology (IF: 11.79), 2021, 48: 102194. (Corresponding author).    
  13.  Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. Bhattacharjee G, Gohil N, Khambhati K, Mani I, Maurya R, Karapurkar JK, Gohil J, Chu DT, Vu-Thi H, Alzahrani KJ, Show PL, Rawal RM, Ramakrishna S*, Singh V*. Journal of Controlled Release, (IF: 11.47), 2022, 343:703-723. *(Co-Corresponding author).  
  14. Genome-wide screening for deubiquitinase subfamily identifies ubiquitin-specific protease 49 as a novel regulator of odontogenesis. Kaushal K, Kim EJ, Tyagi A, Karapurkar JK, Haq S, Jung HS*, Kim KS*, Ramakrishna S*. Cell Death and Differentiation (IF: 15.8). 2022, 29: 1689-1704. *(Co-Corresponding author). 
  15. Dual role of deubiquitinating enzyme USP19 regulates mitotic progression and tumorigenesis by stabilizing survivin. Chandrasekaran AP, Tyagi A, Poondla N, Sarodaya N, Karapurkar JK, Kaushal K, Park CH, Hong SH, Kim KS*, Ramakrishna S*. Molecular Therapy (IF: 11.45). 2022, In Press. *(Co-Corresponding author). 
  16. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells. Tyagi A, Kaushal K, Chandrasekaran AP, Sarodaya N, Das S, Park CH, Hong SH, Kim KS*, Ramakrishna S*. Theranostics (IF: 11.55). 2022, 12(13): 5949-5970. *(Co-Corresponding author). 
  17.  CRISPR-Assisted Phage Engineering for Combatting Multidrug-Resistant Pathogens. Khambhati K, Bhattacharjee G, Gohil N, Dhanoa GK, Sagona AP, Mani I, Bui NL, Chu DT, Karapurkar JK, Jang SH, Chung HY, Maurya R, Alzahrani KJ, Ramakrishna S, Singh V. Bioengineering and Translational Medicine. (IF: 10.6), 2022, In Press. *(Co-Corresponding author). 
  18. Rewiring of metabolic pathways in yeasts for sustainable production of biofuels. Maurya R, Gohi N, Nixon S, Kumar N, Noronha S, Dhali D, Trabelsi H, Alzahrani K, Reshamwala S, Awasthi MK, Ramakrishna S, and Singh V. Bioresource Technology. 2023, 372:128668. (IF: 11.8).

Patents:

  • Genome-scale screening of ubiquitin-specific proteases a subfamily of deubiquitinating enzymes in individual HEK293 knockout cell lines using CRISPR/Cas9-based sgRNA library kit. Korean Patent 2019. Patent number 10-2036613.

Book Chapters:

  • Cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA for genome editing. Suresh B, Ramakrishna S*, Kim H*. Methods in Molecular Biology. * (Co-corresponding author) 2017, 1507:81-94.
  • Different methods of delivering CRISPR/Cas9 into cells. Chandrasekaran AP, Song M, Kye-Seong Kim* and Ramakrishna S*. Progress in Molecular Biology and Translational Science, 2018, 159:157-176. *(Co-corresponding author).
  • CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals. Karapurkar JK, Antao AM, Kim KS * and Ramakrishna S *. Progress in Molecular Biology and Translational Science (IF: 4.07). 2021, 181:185-229. *(Co-Corresponding author). 
  • Advances in microfluidics devices and its applications in personalized medicines. Maurya R, Gohil N, Bhattacharjee G, Khambhati K, Alzahrani KJ, Ramakrishna S, Chu DT, Singh V. Progress in Molecular Biology and Translational Science (IF: 4.07). 2021, 186(1): 191-201. 
  • Microfluidics for single cell analysis. Maurya R, Gohi N, Bhattacharjee G, Alzahrani KJ, Ramakrishna S and Singh V. Progress in Molecular Biology and Translational Science (IF: 4.07). 2021, 186(1): 203-215.

  • Microfluidics device for drug discovery screening and delivery. Maurya R, Gohi N, Bhattacharjee G, Alzahrani KJ, Ramakrishna S and Singh V. Progress in Molecular Biology and Translational Science (IF: 4.07). 2021, 187(1): 335-346.

  • Amyloid precursor protein in Alzheimer’s disease. Maurya R, Bhattacharjee G, Khambhati K, Gohi N,  Singh P, Mani I, Chu D-T, Ramakrishna S, Show P-L and Singh V. Progress in Molecular Biology and Translational Science (IF: 4.07). 2022, In Press.

Research and Review articles:

2023

116. E3 Ubiquitin ligase APC/Cdh1 regulates SLC35F2 protein turnover and inhibits cancer progression in HeLa cells. Colaco JC, Chandrasekaran AP, Karapurkar JK, Gowda ADA, Birappa G, Rajkumar S, Suresh B, Ko N, Hong SH, Oh SJ*, Kim KS*, Ramakrishna S*. BBA-General Subjects. 2023, In Press.   *(Co-Corresponding author).

115. CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis. Karapurkar JK, Kim MS, Colaco JC, Suresh B, Sarodaya N, Kim DH, Park CH, Hong SH, Kim KS*, Ramakrishna S*. Journal of Experimental Clinic and Cancer Research. 2023 42: 121. (IF: 12.65). *(Co-Corresponding author).

114. Nanotechnology and nucleic acid nanoparticles for metabolic disorders. Chu DT,Thi HV, Nguyen TT, Vu TD, Thi YV, Mani I, Gohil N, Bhattacharjee G, Ramakrishna S, Singh V. OpenNano. In Press.

113. USP19 negatively regulates p53 and promotes cervical cancer progression. Tyagi A, Karapurkar JK, Colaco JC, Sarodaya N, Antao AM, Kaushal K, Haq S, Chandrasekaran AP, Das S, Singh V, Singh V, Hong SH, Suresh B*, Kim KS*, Suresh Ramakrishna*. *(Co-Corresponding author). Molecular biotechnology. In Press. 

112. Exploring the potential of microfluidics for next-generation drug delivery systems. Bhattacharjee G, Gohil N, Shukla M, Sharma S, Mani I, Pandya A, Chu DT, Bui NL, Thi YN, Khambhati K, Maurya R, Ramakrishna S, Singh V. OpenNano. In Press. 

111. CRISPR-dCas9 system for epigenetic editing towards therapeutic applications. Bhattacharjee G, Gohil N, Siruka D, Khambhati K, Maurya R, Ramakrishna S, Chu DT, Singh V. Progress in Molecular Biology and Translational Science, 2023, 198:15-24. (IF: 4.07).

110. Production and optimization of lantibiotics. Maurya R, Singh P, Bhattacharjee G, Khambhati K, Gohil N, Gohil J, Kumar V, Ramakrishna S, Singh V. Advances in Biotechnology and Bioengineering. Chapter 22, 2023, 461-471. 

109. Rewiring of metabolic pathways in yeasts for sustainable production of biofuels. Maurya R, Gohi N, Nixon S, Kumar N, Noronha S, Dhali D, Trabelsi H, Alzahrani K, Reshamwala S, Awasthi MK, Ramakrishna S, and Singh V. Bioresource Technology. 2023, 372:128668. (IF: 11.8).

108. Low density lipoprotein receptor endocytosis in cardiovascular disease and the factors affecting LDL levels. Maurya R, Bhattacharjee G, Gohi N, Khambhati K, Shakhreliya S, Bhatnagar A,  Singh P, Ramakrishna S, and Singh V. Progress in Molecular Biology and Translational Science, 2023, 194:333-345. (IF: 4.07).

107. Amyloid precursor protein in Alzheimer’s disease. Maurya R, Bhattacharjee G, Khambhati K, Gohi N,  Singh P, Mani I, Chu D-T, Ramakrishna S, Show P-L and Singh V. Progress in Molecular Biology and Translational Science (IF: 4.07). 2023, In Press.

2022

106. Human pluripotent stem cell-derived macrophages and macrophage-derived exosomes: Therapeutic potential in pulmonary fibrosis. Rasaei R, Tyagi A, Rasaei S,  Lee SJ, Yang SR, Kim KS, Ramakrishna S*, Hong SH*. Stem Cell Research and Therapy (IF: 6.832). 2022, 13: 433. *(Co-Corresponding author).

105. Deubiquitinase USP19 stabilizes and promotes enzymatic activity of phenylalanine hydroxylase variants. Sarodaya N, Tyagi A, Kim HJ, Kang JS, Singh V, Hong SH, Kim WJ, Kim KS*, Ramakrishna S*. Scientific Reports (IF: 4.37). 2022, 12:14243. *(Co-Corresponding author).

 

104. Biosynthesis and characterization of Serratia marcescens derived silver nanoparticles: Investigating its antibacterial, anti-biofilm potency and molecular docking analysis with biofilm-associated proteins. Bhattacharjeea G, Gohila J, Gohila N, Chaudharia H, Gangapuram B, Khambhati K, Mauryaa R, Alzahrani KJ, Ramakrishna S, Singh V. Journal of Molecular Liquids. (IF: 6.16), 2022, 365: 120094. 

 

103. Hybrid nanocomposite coatings from PEDOT and BN-TiO2 nanosheets: enhanced invitro corrosion, wettability and biocompatibility for biomedical applications. Kumar AM, Khan A, Hussein M.A., Khan MY, Dafalla H, Suresh B, Ramakrishna S. Progress in Organic Coatings. (IF: 5.16), 2022, 170: 106946. 

 

102. Novel polymer nanocomposite based on polypyrrole and ZrO2 reinforced BN nanosheets: Prospective utilization as implant coatings for TiNbZr bio-implant alloy. Kumar AM, Khan MY, Khan A, Husseina M.A., Dafalla H, Jang SW, Ramakrishna S. Materials Chemistry and Physics. (IF: 4.09), 2022, 287: 126205. 

 

101. Phage Engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens. Khambhati K, Bhattacharjee G, Gohil N, Dhanoa GK, Sagona AP, Mani I, Bui NL, Chu DT, Karapurkar JK, Jang SH, Chung HY, Maurya R, Alzahrani KJ, Ramakrishna S, Singh V. Bioengineering and Translational Medicine. (IF: 10.6), 2022, In Press. *(Co-Corresponding author).  

 

100. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells. Tyagi A, Kaushal K, Chandrasekaran AP, Sarodaya N, Das S, Park CH, Hong SH, Kim KS*, Ramakrishna S*. Theranostics (IF: 11.55). 2022, 12(13): 5949-5970. *(Co-Corresponding author). 

99. Dual role of deubiquitinating enzyme USP19 regulates mitotic progression and tumorigenesis by stabilizing survivin. Chandrasekaran AP, Tyagi A, Poondla N, Sarodaya N, Karapurkar JK, Kaushal K, Park CH, Hong SH, Kim KS*, Ramakrishna S*. Molecular Therapy (IF: 11.45). 2022, In Press. *(Co-Corresponding author). 
 
98. Gut microbiota in gastrointestinal diseases. Bhattacharjee G, Khambhati K, Gohil N, Singh P, Gohil J, Gautam H, Maurya R, Chu DT, Ramakrishna S and Singh V. Progress in Molecular Biology and Translational Science. (IF: 4.07). 2022, 191(1): 141-151. 
 

97. Self-assembled living materials and their applications. Maurya R, Bhattacharjee G, Gohil N, Khambhati K, Gohil J, Alzahrani KJ, Ramakrishna S, Chu DT, Show PL and Singh V. Design, Principle and Application of Self-assembled Nanobiomaterials in Biology and Medicine. 2022, In Press.

 

96. Deubiquitinase USP19 enhances phenylalanine hydroxylase protein stability and its enzymatic activity. Sarodaya N, Tyagi A, Kim HJ, Colaco JC, Kang JS, Kim WJ, Kim KS*, Ramakrishna S*. Cell Biology and Toxicology. (IF: 6.69), 2022, In Press. *(Co-Corresponding author). 

 

95. Genome-wide screening for deubiquitinase subfamily identifies ubiquitin-specific protease 49 as a novel regulator of odontogenesis. Kaushal K, Kim EJ, Tyagi A, Karapurkar JK, Haq S, Jung HS*, Kim KS*, Ramakrishna S*. Cell Death and Differentiation (IF: 15.8). 2022, 29: 1689-1704. *(Co-Corresponding author). 

94. Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. Bhattacharjee G, Gohil N, Khambhati K, Mani I, Maurya R, Karapurkar JK, Gohil J, Chu DT, Vu-Thi H, Alzahrani KJ, Show PL, Rawal RM, Ramakrishna S*, Singh V*. Journal of Controlled Release, (IF: 11.47), 2022, 343:703-723. *(Co-Corresponding author).  

93. The role of the CRISPR-Cas system in cancer drug development: Mechanisms of action and therapy. Chandrasekaran AP, Karapurkar JK,Chung HY, Ramakrishna S. Biotechnology Journal (IF: 4.67). 2022,17(7): e2100468. (Corresponding author).  

92. Genome-wide CRISPR/Cas9-based screening for Deubiquitinase subfamily identifies ubiquitin-specific protease 11 as a novel regulator of osteogenic differentiation. Kaushal K, Tyagi A, Karapurkar JK, Kim EJ, Tanguturi P, Kim KS*, Jung HS*, Ramakrishna S*. International Journal of Molecular Science (IF: 6.02). 2022. 23(2): 856. *(Co-Corresponding author). 

91. Microfluidics device for drug discovery screening and delivery. Maurya R, Gohi N, Bhattacharjee G, Alzahrani KJ, Ramakrishna S and Singh V. Progress in Molecular Biology and Translational Science (IF: 4.07). 2022, 187(1): 335-346.

90. CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression. Haq S, Sarodaya N, Karapurkar JK, Suresh B, Jo JK, Singh V, Bae YS, *Kim KS and *Ramakrishna S. Cancer Letters (IF: 8.67), 2022, 525: 146-157. *(Co-Corresponding author).  

89. Microfluidics for single cell analysis. Maurya R, Gohi N, Bhattacharjee G, Alzahrani KJ, Ramakrishna S and Singh V. Progress in Molecular Biology and Translational Science (IF: 4.07). 2022,186(1): 203-215.

2021

88. Redox regulation of DUBs and its therapeutic implications in cancer. Tyagi A, Haq S and Ramakrishna S. Redox Biology (IF: 11.79), 2021, 48: 102194. (Corresponding author).  

87. Smart vitamin micelles as cancer nanomedicines for enhanced intracellular delivery of doxorubicin. Ko NR, Lee SJ, Chandrasekaran AP, Tyagi A, Ramakrishna S, Kim SY, Kim DW, Pack CG and Oh SJ. International Journal of Molecular Sciences (IF: 5.9). 2021, 22,20, 11298.

86. Advances in microfluidics devices and its applications in personalized medicines. Maurya R, Gohil N, Bhattacharjee G, Khambhati K, Alzahrani KJ, Ramakrishna S, Chu DT, Singh V. Progress in Molecular Biology and Translational Science (IF: 4.07). 2022, 186(1): 191-201. 

85. USP32 conferes cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. Chandrasekaran AP, Kaushal K, Park CH, Kim KS* and Ramakrishna S*. Theranostics (IF: 11.6). 2021, 11:9752-9771.*(Co-Corresponding author).  

84. USP48 governs cell cycle progression by regulating the protein level of Aurora B. Antao AM, Kaushal K, Das S, Singh V, Suresh B, Kim KS* and Ramakrishna S*. International journal of Molecular Science (IF: 5.9). 2021, 22: 8508. *(Co-Corresponding author).  

83. Bioactive lipid O-cyclic phytosphingosine-1-phosphate promotes differentiation of Human embryonic stem cells into cardiomyocytes via ALK3/BMPR signaling. Jang JH, Kim MS, Antao AM, Jo WJ, Kim HJ, Kim SJ, Choi MJ, Ramakrishna S* and Kim KS*. International journal of Molecular Science (IF: 5.9). 2021, 22: 7015. *(Co-Corresponding author).  

82. Ubiquitin-specific protease 29 regulates Cdc25A-mediated tumorigenesis. Chandrasekaran AP, Woo SH, Sarodaya N, Rhie BH, Tyagi A, Das S, Suresh B, Ko NR, Oh SJ*, Kim KS* and Ramakrishna S*.  International journal of Molecular Science (IF: 5.9). 2021, 22: 5584. *(Co-Corresponding author).  

81. Ubiquitin specific protease 29 functions as an Oncogene promoting tumorigenesis in colorectal carcinoma. Chandrasekaran AP, Suresh B, Sarodaya N, Ko NR, Oh SH*, Kim KS*, Ramakrishna S*. Cancers (IF: 6.6). 2021, In press. *(Co-Corresponding author).  

80. Ubiquitin-specific Protease 3 deubiquitinates and stabilizes Oct4 protein in human embryonic stem cells. Rhie BH, Antao AM, Karapurkar JK, Kim MS, Jo WJ, Ramakrishna S* and Kim KS*. International journal of Molecular Science (IF: 5.9). 2021, 22: 5584. *(Co-Corresponding author).  

79. CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals. Karapurkar JK, Antao AM, Kim KS * and Ramakrishna S *. Progress in Molecular Biology and Translational Science (IF: 4.07). 2021, In Press. *(Co-Corresponding author).  

78. The role of NKX3.1 in cancers and stemness. Antao AM, Ramakrishna S * and Kim KS *. International Journal of stem cells (IF: 2.5), 2021, In Press. *(Co-Corresponding author).

 

2020

77. E3 Ubiquitin ligase APC/C Cdh1 negatively regulates FAH protein stability by promoting its polyubiquitination. Kaushal K, Woo SH, Tyagi A, Kim DH, Suresh B, Kim KS*, Ramkrishna S*. International Journal of Molecular Science (IF: 4.5), 2020, 21:8719. *(Co-Corresponding author).

76. E3 Ubiquitin ligase APC/C Cdh1 regulation of phenylalanine hydroxylase stability and function. Tyagi A, Sarodaya N, Kaushal K, Chandrasekaran AP, Antao AM, Suresh B, Rhie BH, Kim KS*, Ramakrishna S*. International Journal of Molecular Science (IF: 4.5), 2020, 21: 9076. *(Co-Corresponding author).

75. Genome-scale screening of deubiquitinase subfamily identifies USP3 as a stabilizer of Cdc25A regulating cell cycle in cancer. Das S, Chandrasekaran AP, Suresh B, Haq S, Kang JH, Lee SJ, Kim J, Kim J, Lee S, Kim HH*, Kim KS* and Ramakrishna S*. Cell Death and Differentiation (IF: 10.1), 2020, 27:3004-3020. *(Co-Corresponding author).

74. Deubiquitinating enzyme-mediated signaling networks in cancer stem cells. Kaushal K and Ramakrishna S*. Cancers (IF: 6.1), 2020, 12:3253.*(Corresponding author).

73. Disease modeling and stem cell immunoengineering in regenerative medicine using CRISPR/Cas9 systems. Antao AM, Karapurkar JK, Lee DR, Kim KS*, Ramakrishna S*. Computational and Structural Biotechnology Journal. (IF: 6.01) 2020, 18:3649-3665. *(Co-Corresponding author).

72. HAUSP stabilizes Cdc25A and protects cervical cancer cells from DNA damage response. Das S, Chandrasekaran AP, Jo KS, Ko Na Re, Oh SJ*, Kim KS*, Ramakrishna S*. BBA Molecular Cell Research (IF: 4.1), 2020, 1867:118835. *(Co-Corresponding author).

71. Protein degradation and the pathologic basis of Phenylketonuria and hereditary tyrosinemia. Sarodaya N, Suresh B, Kim K* and Ramakrishna S*. International Journal of Molecular Science (IF: 4.5), 2020, 21(14): 4996. *(Co-Corresponding author).

70.  Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics. Antao AM, Tyagi A, Kim KS* and Ramakrishna S*. Cancers (IF: 6.1), 2020, 12:1579 *(Co-Corresponding author).

69.  YM155 sensitizes TRAIL-mediated apoptosis through cFLIP and survivin downregulation in HeLa cells. Chandrasekaran AP, Poondla N, Ko Na Re, Oh SJ*, Ramakrishna S*. Oncology Letters (IF: 1.55), 2020, 20:72 *(Co-Corresponding author).

68.  The role of deubiquitinating enzymes in hematopoiesis and hematological malignancies. Sarodaya N, Karapurkar J, Kim KS, Hong SH*, Ramakrishna S*. Cancers (Basel) (IF: 6.1), 2020, 12(5):1103. *(Co-Corresponding author).

67.  Importance of Deubiquitination in Macrophage-Mediated Viral Response and Inflammation. Rasaei R, Sarodaya N, Kim KS, Ramakrishna S, Hong SH. International Journal of Molecular Science. (IF: 4.5). 2020, 21:8090. *(Co-Corresponding author).

66.  Preparation and characterization of Pectin/Polypyrrole based multifunctional coatings on TiNbZr alloy for orthopaedic applications. Kumar AM, Adesina AY, Hussein M.A, Umoren SA, Ramakrishna S, Saravanan S. Carbohydrate Polymers (IF: 6.04), 2020, 242: 116285.

65.  The role of deubiquitinating enzymes in cancer drug resistance. Tanguturi P, Kim KS* and Ramakrishna S*. Cancer Chemotherapy and Pharmacology (IF: 2.73), 2020, 85(4): 627-639. *(Co-Corresponding author).

64.  Critical roles of deubiquitinating enzymes in the nervous system and neurodegenerative disorders. Das S, Ramakrishna S* and Kim KS*. Molecules and Cells (IF: 3.53), 2020, 43(3): 203-214. *(Co-Corresponding author).

2019

63.  CRISPR-mediated upregulation of DR5 and downregulation of cFLIP synergistically sensitize HeLa cells to TRAIL-mediated apoptosis. Poondla N, Chandrasekaran AP, Heese K, Kim KS* and Ramakrishna S*. Biochemical and Biophysical Research Communications (IF: 2.46), 2019, 512: 60-65. *(Co-Corresponding author).

62.  Deubiquitinating enzymes as cancer biomarkers: New therapeutic opportunities? Poondla N, Chandrasekaran AP, Kim KS*, Ramakrishna S*. BMB Reports (IF:3.1), 2019, 52:181-189. *(Co-Corresponding author).

61.  En bloc and segmental deletions of human XIST reveal X chromosome inactivation-involving RNA elements. Lee H, Gopalappa R, Hongjae S, Choi S, Ramakrishna S, Lee J, Kim HH, Nam JW. Nucleic Acid Research (IF: 11.5), 2019, 47:3875-3887.

60.  The stability and oncogenic function of LIN28A are regulated by USP28. Haq S, Das S, Kim D, Chandrasekaran AP, Hong SH, Kim KS, Ramakrishna S. Biochim Biophy Acta Molecular Basis of Disease (IF: 5.108), 2019, 1865(3):599-610. (Corresponding author).

59.  PEDOT/FHA nanocomposite coatings on newly developed Ti-Nb-Zr implants: Biocompatibility and Surface protection against corrosion and bacterial infections. Madhan KA, Saravanan S, Akhtar S, Al-Aqeeli, Adesina A, Ramakrishna S, Materials Science and Engineering C, (IF: 5.08), 2019, 98: 482-495.

2018

58.  Transcriptional activation of LGR5 gene by an engineered CRISPR-Cas9-based system induces hepatic-specific factors. Kim DH, Kim KS*, Ramakrishna S*. Indian Journal of Biotechnology (IF: 0.368), 2018, 17:561-568. *(Co-corresponding author).

57.  NFAT5 promotes in vivo development of murine melanoma metastasis. Kim DH, Kim KS*, Ramakrishna S*. Biochemical and Biophysical Research Communications (IF: 2.46), 2018, 505(3):748-754. *(Co-corresponding author).

56.  Deubiquitinating enzymes in cancer stem cells: functions and targeted inhibition for cancer therapy. Kaushal K, Antao AM, Kim KS* and Ramakrishna S*. Drug Discovery Today (IF: 6.84), 2018, 23(12):1974-1982. *(Co-corresponding author)

55.  In vivo gene correction with targeted sequence substitution through microhomology-mediated end joining. Shin JH, Jung S, Ramakrishna S, Kim HH, Lee J. Biochemical and Biophysical Research Communications (IF: 2.3), 2018, 502(1):116-122.

54.  Brain somatic mosaicisms in MTOR disrupt neuronal ciliogenesis leading to focal cortical dyslamination. Park SM, Lim JS, Ramakrishna S, Kim SH, Kim WK, Lee J, Kang HC, Reiter JF, Kim DS, Kim HH, Lee JH. Neuron (IF: 14.02), 2018, 99:83-97.

53.  Efficient genome editing by FACS enrichment of paired D10A Cas9 nickases coupled with fluorescent proteins. Gopalappa R, Song M, Chandrashekaran AP, Das S, Haq S and Ramakrishna. Archieves of Pharmacal research (IF: 2.32), 2018, 41(9):911-920. (Corresponding author)

52.  Influence of Surface Treatment on PEDOT Coatings: Surface and Electrochemical Corrosion Aspects of Newly Developed Ti Alloy. Madhankumar A.; Hussein M.A. ; Yusuf Adesina A; Ramakrishna S, Al-Aqeeli, N. RSC Advances (IF:3.11), 2018, 8: 19181-19195

51.  Scaffolding protein RanBPM and its interactions in diverse signaling pathways in health and disease. Das S, Haq S and Ramakrishna S. Discovery Medicine (IF: 2.4), 2018, 25(138):177-194. (Corresponding author)

50.  Paired D10A Cas9 nickases are sometimes more efficient than individual nucleases for gene disruption. Gopalappa R, Suresh B, Ramakrishna S* and Kim HH*. Nucleic Acid Research (IF:10.16), 2018, 46(12):e71. *(Co-corresponding author).

49.  Different methods of delivering CRISPR/Cas9 into cells. Chandrasekaran AP, Song M, Kye-Seong Kim* and Ramakrishna S*. Progress in Molecular Biology and Translational Science (IF: 2.98), 2018, 159:157-176. *(Co-corresponding author).

48.  Genome Editing in Stem Cells for Disease Therapeutics. Song M* and Ramakrishna S*. Molecular Biotechnology (IF: 1.63), 2018, 60(4):329-338, *(Co-corresponding author).

47.  Deubiquitylating enzymes as cancer stem cell therapeutics. Haq S, Suresh B*, Ramakrishna S*. BBA reviews on Cancers (IF: 9.452), 2018, 1869: 1-10 *(Co-corresponding author).

2017

46.  Electrochemical synthesis and surface protection of polypyrrole-CeO2 nanocomposite coatings on AA2024 alloy. A Kumar, Babu S, Ramakrishna S, Barros Ana. Synthetic Metals (IF: 2.4) 2017, 234: 18-28.

45.  RanBPM: a potential therapeutic target for modulating diverse physiological disorders. Das S, Suresh B, Kim HH*, Ramakrishna S*. Drug Discovery Today (IF: 6.37), 2017, 22: 1816-1824. *(Co-corresponding author).

44.  Future application of deubiquitylating enzymes for rapid and efficient cellular reprogramming. Haq S and Ramakrishna S*. Journal of Stem Cell Research and Therapeutics, 2017, 2(6): 00083. *(Corresponding author).

43.  Promising bio-composites of polypyrrole and chitosan: Surface protective and in vitro biocompatibility performance on 316L SS implants. A Kumar*, Suresh B, Das S, Obot I.B and Ramakrishna S*. Carbohydrate Polymers (IF: 4.22), 2017, 173: 121-130. *(Co-corresponding author)

42.  Deubiquitylation of Deubiquitylases. Haq S and Ramakrishna S*. Open Biology (IF: 4.82), 2017, 7:170016. *(Corresponding author).

41.  Genome editing: a robust technology for human stem cells. Chandrasekaran AP, Song M*, Ramakrishna S*. Cellular in Molecular Life Science (IF: 69), 2017, 74: 3335-3346. *(Co-corresponding author).

40.  Somatic Mutations in TSC1 and TSC2 cause focal cortical dysplasia. Lim JS, Gopalappa R, Kim SH, Ramakrishna S, Lee M, Kim W, Kim J, Park SM, Lee J, Oh JH, Kim HD, Park CH, Lee JS, Kim S, Kim DS, Han JM, Kang HC, Kim H, Lee JH. American Journal of Human Genetics (IF:11.20), 2017, 100:454-472.

39.  Cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA for genome editing. Suresh B, Ramakrishna S*, Kim H*. Methods in Molecular Biology, 2017, 1507: 81-94. *(Co-corresponding author).

2016

38.  Regulation of pluripotency and differentiation by deubiquitinating enzymes. Suresh B, Lee J, Kim H*, Ramakrishna S*. Cell Death and Differentiation. (IF: 8.1), 2016, 23: 1257-64. (Co-Corresponding Author).

37.  Fate determination of stem cells by deubiquitinating enzymes. Chandrasekaran AP, Suresh B, Kim H, Kim KS*, Ramakrishna S*. Stem Cells. (IF:6.59), 2016, In Press (Co-Corresponding Author).

36.  Dissecting MicroRNA-Mediated Regulation of Stemness, Reprogramming, and Pluripotency. Lee, YJ., Ramakrishna S., Chauhan, H., Park, WS., Kim, KS., and Hong, SH. Cell Regeneration. 2016, 5:2 (Co-First Author).

35.  Ubiquitin-specific protease 11 functions as a tumor suppressor by modulating Mgl-1 protein to regulate cancer cell growth. Lim, K.-H., Suresh, B., Park, J.-H., Kim, Y.-S., Ramakrishna S., and Baek, K.-H. (IF: 6.359), 2016, 7:14441-57.

34.  Importance of ubiquitination and deubiquitination in cellular reprogramming. Suresh B, Lee J, Kim KS*, Ramakrishna S*. Stem cells Int. (IF: 2.813; SCIE), 2016, 2016:6705927. (Co-corresponding author).

2015

33.  Biocompatible Responsive Polypyrrole/GO nanocomposite coatings for biomedical applications. A Kumar, Suresh B, Ramakrishna S, Kim KS, Gasem ZMA. RSC Advances. (IF: 2.562; SCIE), 2015, 5: 99866-74.

32.  CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods. Jo YI, Suresh B, Kim H, Ramakrishna S. BBA- Rev Cancer (IF: 7.584; SCI), 2015, 1856: 234-43. (Corresponding author).

31.  The role of deubiquitinating enzymes in spermatogenesis. Suresh B, Lee J, Hong SH, Kim KS*, Ramakrishna S*. Cell Mol Life Sci. (IF: 5.8; SCI), 2015, 72: 4711-20. (Co-corresponding author).

30.  Regulation of Fanconi anemia protein FANCD2 monoubiquitination by miR-302. Suresh B, Kumar AM, Jeong HS, Cho YH, Ramakrishna S*, Kim KS*. (Co-corresponding author). Biochem Biophys Res Commun. (IF: 2.8; SCI), 2015, 466: 180-185.

29.  Recent developments and clinical studies utilizing engineered zinc finger nuclease technology. Jo YI, Kim H, Ramakrishna S. (Corresponding author), Cell Mol Life Sci (IF: 5.8; SCI), 2015, 72:3819-30.

2014 (Post-doctoral fellowship achievements)

28.  Effective gene delivery to human stem cells with a cell-targeted peptide-modified bioreducible polymer. Beloor J*, Ramakrishna S*, Nam K, Choi C, Kim SH, Cho HJ, Shin HS, Kim H, Kim SW, Lee SK, Kumar P (*equally contributed). Small (IF: 7.514; SCI), 2014, doi: 10.1002/smll.201402933.

27.  Biological functions of hyaluronan and cytokine-inducible deubiquitinating enzymes. Ramakrishna S*, Suresh B*, Baek KH. (*equally contributed) BBA- Rev Cancer (IF: 7.584; SCI), 2014, 1855:83-91.

26.  Enhanced gene disruption by programmable nucleases delivered by a minicircle vector. Kwaku Dad AB*, Ramakrishna S*, Song M, Kim H (*equally contributed). Gene Ther. (IF: 4.321; SCI), 2014, 21:921-30.

25. Surrogate reporter-based enrichment of cells containing RNA-guided Cas9 nuclease- induced mutations. Ramakrishna S, Cho SW, Kim S, Song M, Gopalappa R, Kim JS, Kim H. Nat Commun. (IF: 10.015; SCI) (Cited: 7), 2014 Feb 26; 5: 3378.

24.  Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Ramakrishna S, Kwaku Dad AB, Beloor J, Gopalappa R, Lee SK, Kim H. Genome Res. (IF:  14.397; SCI) (Cited: 5), 2014, 24:1020-7.

23.  Enrichment of cells with TALEN-induced mutations using surrogate reporters. Kim YH*, Ramakrishna S*, Kim H, Kim JS (*equally contributed). Methods. (IF: 3.641; SCI) (Cited: 2), 2014. 69:108-17.

22.  Posttranslational Modifications of Defined Embryonic Reprogramming Transcription Factors. Ramakrishna S, Kim KS, Baek KH. Cell Reprogram. (IF:2.74; SCIE) (Cited: 3), 2014 Apr 16(2): 108-20.

21.  Electrochemical and in vitro bioactivity of Polypyrrole/Ceramic nanocomposite coatings on 316L SS bio-implants. Madan Kumar A, Nagarajan S, Ramakrishna S, Sudhagar P, Kang YS, Kim H, Gasem ZMA, Rajendran N. Mater Sci Eng C Mater Biol Appl. (IF: 2.74; SCIE) 2014. 43:76-85.

20.  Multi-Functional Ceramic Hybrid Coatings on Biodegradable AZ31 Mg Implants: Electrochemical, Tribological and Quantum Chemical Aspects for Orthopaedic applications. Madan Kumar A, Thangavel E, Ramakrishna S, Obot IB, Gasem ZMA, Kim H, and Kim DE. RSC Adv. (IF: 2.562; SCIE), 2014, 4:24272-85

19.  An electrochemical, in vitro bioactivity, and quantum chemical approach to nanostructured copolymer coatings for orthopedic applications. Madan Kumar A, Ramakrishna S, Sudhagar P, Kim H, Kang YS, Obot IB, Gasem ZMA. J Mater Sci. (IF: 2.163; SCI) (Cited: 3), 2014 Feb 28.49:4067-80.

18.  Evaluation of chemically modified Ti-5Mo-3Fe alloy surface: Electrochemical aspects and in vitro bioactivity on MG63 cells. Madhan Kumar A, Sudhagar P, Ramakrishna S, Kang YS, Kim H, Gasem ZMA, Rajendran N. Appl Surf Sci. (IF: 2.112; SCI), 2014, 307: 52-61.

17.  Critical lysine residues of Klf4 required for protein stabilization and degradation. Lim KH, Kim SR, Ramakrishna S, Baek KH. Biochem Biophys Res Commun. (IF: 2.406; SCI), 2014 Jan 24; 443(4):1206-10.

2013

16.  Molecular mechanisms and functions of cytokine-inducible deubiquitinating enzymes. Lim KH, Ramakrishna S, Baek KH. Cytokine Growth Factor Rev. (IF: 8.831; SCI) (Cited: 1), 2013 Oct; 24(5):427-31.

15.  Stability of zinc finger nuclease protein is enhanced by the proteasome inhibitor MG132. Ramakrishna S, Kim YH, Kim H. PLoS One. (IF: 092; SCIE) (Cited: 8), 2013; 8(1):e54282.

2012

14.  Hyaluronan binding motifs of USP17 and SDS3 exhibit anti-tumor activity. Ramakrishna S, Suresh B, Bae SM, Ahn WS, Lim KH, Baek KH. PLoS One. (IF: 4.411; SCIE) (Cited: 4), 2012; 7(5):e37772.

13.  Diverse roles of the scaffolding protein RanBPM. Suresh B, Ramakrishna S, Baek KH. Drug Discov Today. (IF: 6.422; SCI) (Cited: 18), 2012 Apr; 17(7-8):379-87.

2011 (Ph.D publications)

12.  LCP1 up-regulated by partial pancreatectomy supports cell proliferation and differentiation. Choi JH, Lee MY, Ramakrishna S, Kim Y, Shim JY, Han SM, Kim JY, Lee DH, Choi YK, Baek KH. Mol Biosyst. (IF: 3.825; SCI) (Cited: 1), 2011 Nov; 7(11):3104-11.

11.  PEST motif sequence regulating human NANOG for proteasomal degradation. Ramakrishna S*, Suresh B*, Lim KH, Cha BH, Lee SH, Kim KS, Baek KH (*equally contributed). Stem Cells Dev. (IF: 4.791; SCI) (Cited: 33), 2011 Sep; 20(9):1511-9.

10.  Protein stability of mitochondrial superoxide dismutase SOD2 is regulated by USP36. Kim MS, Ramakrishna S, Lim KH, Kim JH, Baek KH. J Cell Biochem. (IF: 3.42; SCI) (Cited: 6), 2011 Feb; 112(2):498-508.

9.  Lys-63-specific deubiquitination of SDS3 by USP17 regulates HDAC activity. Ramakrishna S, Suresh B, Lee EJ, Lee HJ, Ahn WS, Baek KH. J Biol Chem. (IF: 5.328; SCI) (Cited: 13), 2011 Mar 25; 286(12):10505-14.

8.  The role of deubiquitinating enzymes in apoptosis. Ramakrishna S, Suresh B, Baek KH. Cell Mol Life Sci. (IF: 7.04; SCI) (Cited: 34), 2011 Jan; 68(1):15-26.

2010

7.  Stability and function of mammalian lethal giant larvae-1 oncoprotein are regulated by the scaffolding protein RanBPM. Suresh B, Ramakrishna S, Kim YS, Kim SM, Kim MS, Baek KH. J Biol Chem. (IF: 5.328; SCI) (Cited: 16), 2010 Nov 12; 285(46):35340-9.

6.  Polyclonal and monoclonal antibodies specific for USP17, a proapoptotic deubiquitinating enzyme. Ramakrishna S, Suresh B, Kang IC, Baek KH. Hybridoma (Larchmt) (IF: 0.33; SCIE) (Cited: 1). 2010 Aug; 29(4):311-9.

5.  K48- and K63-linked polyubiquitination of deubiquitinating enzyme USP44. Suresh B, Ramakrishna S, Lee HJ, Choi JH, Kim JY, Ahn WS, Baek KH. Cell Biol Int. (IF: 1.64; SCIE) (Cited: 7), 2010 Aug; 34(8):799-808.

2009

4.  USP7 (ubiquitin specific         peptidase      7(herpes       virus-associated)). Baek KH and Ramakrishna S. Atlas Genet Cytogenet Oncol Haematol. 2009 13(8): 576-579.

3.  Association between a single nucleotide polymorphism in MTHFR gene and polycystic ovary syndrome. Choi SW, Gu BH, Ramakrishna S, Park JM, Baek KH. Eur J Obstet Gynecol Reprod Biol. (IF: 1.62; SCI) (Cited: 14), 2009 Jul; 145(1):85-8.

2008

2.  Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome. Park JM, Lee EJ, Ramakrishna S, Cha DH, Baek KH. Int J Mol Med. (IF: 1.96; SCI) (Cited: 18), 2008 Aug; 22(2):249-54.

2007

1. Transient HEK293 Recombinant Protein Production Flow:The Replenishment of Protein Batches By Outsourcing to a Contract Research Organization. Battle T, Anand L, Prasad R, Ramakrishna S, Gandhi A, Kumar A, Delafosse L, Roy N, Antonsson B. BioProcessing Journal, Vol.6/No.4, Winter 2007.c